Status:
COMPLETED
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial has two parts. The purpose of the first part of the trial is to determine the doses of 2 drugs, sunitinib malate and interferon alfa-2b, that can be given safely in combination. This part i...
Eligibility Criteria
Inclusion
- Advanced renal cell carcinoma of clear cell origin or a component of clear cell histology.
- Measurable disease
Exclusion
- Prior systemic therapy of any kind for advanced renal cell cancer
- History of brain metastases
- Uncontrolled hypertension
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
317 Patients enrolled
Trial Details
Trial ID
NCT00267748
Start Date
December 1 2005
End Date
June 1 2010
Last Update
September 5 2011
Active Locations (156)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hot Springs, Arkansas, United States, 71913
2
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
3
Pfizer Investigational Site
Anaheim, California, United States, 92807
4
Pfizer Investigational Site
Baldwin Park, California, United States, 91706